Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.50 |
| ▸ | F10 | P00742 | 3/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | CETP | P11597 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6873900 | 0.89 | GPR119 (0.51) | GPR119F10F2ALKCHEK2 | |
| SCHEMBL6873899 | 0.89 | GPR119 (0.51) | GPR119F10F2ALKCHEK2 | |
| SCHEMBL6864795 | 0.87 | GPR119 (0.51) | GPR119F10F2ALKCHEK2 | |
| SCHEMBL6864800 | 0.87 | GPR119 (0.51) | GPR119F10F2ALKCHEK2 | |
| SCHEMBL3897950 | 0.85 | GPR119 (0.56) | GPR119F10F2ALKHDAC1 | |
| SCHEMBL3899273 | 0.83 | GPR119 (0.48) | GPR119F10F2ALKCHEK2 | |
| SCHEMBL3899270 | 0.83 | GPR119 (0.48) | GPR119F10F2ALKCHEK2 | |
| SCHEMBL6874416 | 0.81 | GPR119 (0.52) | GPR119F10F2ALK | |
| SCHEMBL3912286 | 0.81 | F10 (0.60) | GPR119F10F2ALKL3MBTL1 | |
| SCHEMBL6555353 | 0.79 | CA12 (0.40) | CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784191-B2 | AS BLOOD-COAGULATION INHIBITOR OR AN AGENT FOR THERAPY AND PROPHYLAXIS OF THROMBOSIS OR EMBOLISM, CONTAINING | AJINOMOTO CO., INC. (JP) | 2004-08-31 | — | — | US | disclosed |
| EP-1236735-B1 | BENZAMIDINE DERIVATIVES | AJINOMOTO KK (JP) | 2004-02-25 | — | — | EP | disclosed |
| US-20020193348-A1 | Benzamidine derivatives | AJINOMOTO CO., INC. (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-1236735-A1 | BENZAMIDINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193348-A1 | Benzamidine derivatives | SERPINC1, SERPINE1, TFPI | GPR119 3944/4885F10 14/4885F2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.